{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T12:29:23Z","timestamp":1794227363549,"version":"4.9.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 14042"],"award-info":[{"award-number":["IG 14042"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13046-017-0577-2","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T08:09:40Z","timestamp":1502352580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells"],"prefix":"10.1186","volume":"36","author":[{"given":"Maria Grazia","family":"Atzori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Tentori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ruffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bonanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Scimeca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eskil","family":"Eskilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Daubon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrvoje","family":"Miletic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ricci Vitiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pallini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Bjerkvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"D\u2019Atri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Miguel","family":"Lacal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,10]]},"reference":[{"key":"577_CR1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbrc.2008.07.121","volume":"375","author":"R Roskoski Jr","year":"2008","unstructured":"Roskoski R Jr. VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun. 2008;375:287\u201391.","journal-title":"Biochem Biophys Res Commun"},{"key":"577_CR2","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1248\/bpb.34.1785","volume":"34","author":"S Takahashi","year":"2011","unstructured":"Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011;34:1785\u20138.","journal-title":"Biol Pharm Bull"},{"key":"577_CR3","doi-asserted-by":"crossref","first-page":"re1","DOI":"10.1126\/scisignal.262tr1","volume":"2","author":"Y Cao","year":"2009","unstructured":"Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal. 2009;2:re1.","journal-title":"Sci Signal"},{"key":"577_CR4","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1046\/j.1538-7836.2003.00263.x","volume":"1","author":"M Autiero","year":"2003","unstructured":"Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost. 2003;1:1356\u201370.","journal-title":"J Thromb Haemost"},{"key":"577_CR5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nrc2524","volume":"8","author":"C Fischer","year":"2008","unstructured":"Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer. 2008;8:942\u201356.","journal-title":"Nat Rev Cancer"},{"key":"577_CR6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669\u201376.","journal-title":"Nat Med"},{"key":"577_CR7","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1074\/jbc.271.6.3154","volume":"271","author":"Y Cao","year":"1996","unstructured":"Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA, et al. Heterodimers of placenta growth factor vascular endothelial growth factor - endothelial activity, tumor cell expression, and high affinity binding to Flk-1\/KDR. J Biol Chem. 1996;271:3154\u201362.","journal-title":"J Biol Chem"},{"key":"577_CR8","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/ncomms1977","volume":"3","author":"MJ Cudmore","year":"2012","unstructured":"Cudmore MJ, Hewett PW, Ahmad S, Wang KQ, Cai M, Al-Ani B, et al. The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. Nat Commun. 2012;3:972.","journal-title":"Nat Commun"},{"key":"577_CR9","doi-asserted-by":"crossref","first-page":"ra52","DOI":"10.1126\/scisignal.2003905","volume":"6","author":"A Anisimov","year":"2013","unstructured":"Anisimov A, Lepp\u00e4nen VM, Tvorogov D, Zarkada G, Jeltsch M, Holopainen T, et al. The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal. 2013;6:ra52.","journal-title":"Sci Signal"},{"key":"577_CR10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/cr.2010.77","volume":"20","author":"X Li","year":"2010","unstructured":"Li X. VEGF-B: a thing of beauty. Cell Res. 2010;20:741\u20134.","journal-title":"Cell Res"},{"key":"577_CR11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3858\/emm.2012.44.1.023","volume":"44","author":"KJ Kim","year":"2012","unstructured":"Kim KJ, Cho CS, Kim WU. Role of placenta growth factor in cancer and inflammation. Exp Mol Med. 2012;44:10\u20139.","journal-title":"Exp Mol Med"},{"key":"577_CR12","doi-asserted-by":"crossref","unstructured":"Dewerchin M, Carmeliet P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med. 2012;2.","DOI":"10.1101\/cshperspect.a011056"},{"key":"577_CR13","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1158\/1078-0432.CCR-06-0831","volume":"12","author":"Y Wu","year":"2006","unstructured":"Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res. 2006;12:6573\u201384.","journal-title":"Clin Cancer Res"},{"key":"577_CR14","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/cncr.24789","volume":"116","author":"JD Schwartz","year":"2010","unstructured":"Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y. Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (human antibody targeting vascular endothelial growth factor receptor-1). Cancer. 2010;116:1027\u201332.","journal-title":"Cancer"},{"key":"577_CR15","doi-asserted-by":"crossref","first-page":"72868","DOI":"10.18632\/oncotarget.12108","volume":"7","author":"G Graziani","year":"2016","unstructured":"Graziani G, Ruffini F, Tentori L, Scimeca M, Dorio AS, Atzori MG, et al. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding. Oncotarget. 2016;7:72868\u201385.","journal-title":"Oncotarget"},{"key":"577_CR16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1161\/ATVBAHA.107.158022","volume":"28","author":"V Tchaikovski","year":"2008","unstructured":"Tchaikovski V, Fellbrich G, Waltenberger J. The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. Arterioscler Thromb Vasc Biol. 2008;28:322\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"577_CR17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm884","volume":"9","author":"M Autiero","year":"2003","unstructured":"Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 2003;9:936\u201343.","journal-title":"Nat Med"},{"key":"577_CR18","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.1007\/s13277-015-3548-2","volume":"36","author":"J He","year":"2015","unstructured":"He J, Shen N, Huang X. Thyroid carcinoma cells produce PLGF to enhance metastasis. Tumour Biol. 2015;36:8601\u20137.","journal-title":"Tumour Biol"},{"key":"577_CR19","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1586\/era.09.68","volume":"9","author":"GM Higa","year":"2009","unstructured":"Higa GM, Abraham J. Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther. 2009;9:999\u20131007.","journal-title":"Expert Rev Anticancer Ther"},{"key":"577_CR20","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMcibr1309402","volume":"369","author":"S Das","year":"2013","unstructured":"Das S, Marsden PA. Angiogenesis in glioblastoma. N Engl J Med. 2013;369:1561\u20133.","journal-title":"N Engl J Med"},{"key":"577_CR21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00401-012-1066-5","volume":"124","author":"KH Plate","year":"2012","unstructured":"Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol. 2012;124:763\u201375.","journal-title":"Acta Neuropathol"},{"key":"577_CR22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. European Organisation for Research and Treatment of Cancer brain tumor and radiotherapy groups; National Cancer Institute of Canada clinical trials group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"577_CR23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-016-0303-5","volume":"35","author":"Y Yan","year":"2016","unstructured":"Yan Y, Xu Z, Dai S, Qian L, Sun L, Gong Z. Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016;35:23.","journal-title":"J Exp Clin Cancer Res"},{"key":"577_CR24","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1158\/0008-5472.CAN-07-6241","volume":"68","author":"M Kerber","year":"2008","unstructured":"Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M, et al. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res. 2008;68:7342\u201351.","journal-title":"Cancer Res"},{"key":"577_CR25","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.18632\/oncotarget.6320","volume":"7","author":"M Niyazi","year":"2016","unstructured":"Niyazi M, Harter PN, Hattingen E, Rottler M, von Baumgarten L, Proescholdt M, et al. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Oncotarget. 2016;7:2313\u201328.","journal-title":"Oncotarget"},{"key":"577_CR26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.neulet.2017.02.076","volume":"645","author":"L Lisi","year":"2017","unstructured":"Lisi L, Ciotti GM, Braun D, Kalinin S, Curr\u00f2 D, Dello Russo C, et al. Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in human glioblastoma and the surrounding normal parenchyma. Neurosci Lett. 2017;645:106\u201312.","journal-title":"Neurosci Lett"},{"key":"577_CR27","doi-asserted-by":"crossref","first-page":"8205","DOI":"10.1158\/1078-0432.CCR-08-0644","volume":"14","author":"R Pallini","year":"2008","unstructured":"Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res. 2008;14:8205\u201312.","journal-title":"Clin Cancer Res"},{"key":"577_CR28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/cdd.2012.150","volume":"20","author":"C Ciceroni","year":"2013","unstructured":"Ciceroni C, Bonelli M, Mastrantoni E, Niccolini C, Laurenza M, Larocca LM, et al. Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death Differ. 2013;20:396\u2013407.","journal-title":"Cell Death Differ"},{"key":"577_CR29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13046-015-0163-4","volume":"34","author":"B Wu","year":"2015","unstructured":"Wu B, Sun C, Feng F, Ge M, Xia L. Do relevant markers of cancer stem cells CD133 and nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis. J Exp Clin Cancer Res. 2015;34:44.","journal-title":"J Exp Clin Cancer Res"},{"key":"577_CR30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2407-14-151","volume":"14","author":"L Tentori","year":"2014","unstructured":"Tentori L, Ricci-Vitiani L, Muzi A, Ciccarone F, Pelacchi F, Calabrese R, et al. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. BMC Cancer. 2014;14:151.","journal-title":"BMC Cancer"},{"key":"577_CR31","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/neuonc\/now113","volume":"18","author":"E Eskilsson","year":"2016","unstructured":"Eskilsson E, Rosland GV, Talasila KM, Knappskog S, Keunen O, Sottoriva A, et al. EGFRvIII mutations can emerge as late and heterogeneous events in glioblastoma development and promote angiogenesis through Src activation. Neuro-Oncology. 2016;18:1644\u201355.","journal-title":"Neuro-Oncology"},{"key":"577_CR32","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1242\/jcs.00673","volume":"116","author":"A Orecchia","year":"2003","unstructured":"Orecchia A, Lacal PM, Schietroma C, Morea V, Zambruno G, Failla CM. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the \u03b15\u03b21 integrin. J Cell Sci. 2003;116:3479\u201389.","journal-title":"J Cell Sci"},{"key":"577_CR33","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1046\/j.1523-1747.2000.00199.x","volume":"115","author":"PM Lacal","year":"2000","unstructured":"Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol. 2000;115:1000\u20137.","journal-title":"J Invest Dermatol"},{"key":"577_CR34","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1365-2133.2010.10200.x","volume":"164","author":"F Ruffini","year":"2011","unstructured":"Ruffini F, Failla CM, Orecchia A, Bani MR, Dorio AS, Fortes C, et al. Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression. Br J Dermatol. 2011;164:1061\u201370.","journal-title":"Br J Dermatol"},{"key":"577_CR35","first-page":"525","volume":"27","author":"L Tentori","year":"2005","unstructured":"Tentori L, Vergati M, Muzi A, Levati L, Ruffini F, Forini O, et al. Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. Int J Oncol. 2005;27:525\u201335.","journal-title":"Int J Oncol"},{"key":"577_CR36","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.ejca.2008.06.032","volume":"44","author":"PM Lacal","year":"2008","unstructured":"Lacal PM, Morea V, Ruffini F, Orecchia A, Dorio AS, Failla CM, et al. Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide. Eur J Cancer. 2008;44:1914\u201321.","journal-title":"Eur J Cancer"},{"key":"577_CR37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1756-9966-32-70","volume":"32","author":"Z Mu","year":"2013","unstructured":"Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R, Cristofanilli M. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res. 2013;32:70.","journal-title":"J Exp Clin Cancer Res"},{"key":"577_CR38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13046-016-0455-3","volume":"35","author":"H Xu","year":"2016","unstructured":"Xu H, Chen Q, Wang H, Xu P, Yuan R, Li X, Bai L, Xue M. Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II. J Exp Clin Cancer Res. 2016;35:178.","journal-title":"J Exp Clin Cancer Res"},{"key":"577_CR39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/B:NEON.0000013495.08168.8f","volume":"66","author":"HH Steiner","year":"2004","unstructured":"Steiner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C. Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neuro-Oncol. 2004;66:129\u201338.","journal-title":"J Neuro-Oncol"},{"key":"577_CR40","doi-asserted-by":"crossref","first-page":"78541","DOI":"10.18632\/oncotarget.12398","volume":"7","author":"A D\u2019Alessio","year":"2016","unstructured":"D\u2019Alessio A, Proietti G, Lama G, Biamonte F, Lauriola L, Moscato U, et al. Analysis of angiogenesis related factors in glioblastoma, peritumoral tissue and their derived cancer stem cells. Oncotarget. 2016;7:78541\u201356.","journal-title":"Oncotarget"},{"key":"577_CR41","first-page":"477","volume":"7","author":"Y Yi","year":"2016","unstructured":"Yi Y, Hsieh IY, Huang X, Li J, Zhao W. Glioblastoma stem-like cells: characteristics, microenvironment, and therapy. Front Pharmacol. 2016;7:477.","journal-title":"Front Pharmacol"},{"key":"577_CR42","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. TCGA research network. TCGA research network. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462\u201377.","journal-title":"Cell"},{"key":"577_CR43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.vph.2016.05.011","volume":"86","author":"L Claesson-Welsh","year":"2016","unstructured":"Claesson-Welsh L. VEGF receptor signal transduction - a brief update. Vasc Pharmacol. 2016;86:14\u20137.","journal-title":"Vasc Pharmacol"},{"key":"577_CR44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/bbrc.1998.8578","volume":"246","author":"K Igarashi","year":"1998","unstructured":"Igarashi K, Isohara T, Kato T, Shigeta K, Yamano T, Uno I. Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2. Biochem Biophys Res Commun. 1998;246:95\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"577_CR45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/bj3580465","volume":"358","author":"Y Yu","year":"2001","unstructured":"Yu Y, Hulmes JD, Herley MT, Whitney RG, Crabb JW, Sato JD. Direct identification of a major autophosphorylation site on vascular endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol 3\u2032-kinase binding. Biochem J. 2001;358:465\u201372.","journal-title":"Biochem J"},{"key":"577_CR46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1042\/BJ20110301","volume":"437","author":"S Koch","year":"2011","unstructured":"Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011;437:169\u201383.","journal-title":"Biochem J"},{"key":"577_CR47","first-page":"1399","volume":"9","author":"K Lamszus","year":"2003","unstructured":"Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res. 2003;9:1399\u2013405.","journal-title":"Clin Cancer Res"},{"key":"577_CR48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10456-006-9055-8","volume":"9","author":"M Shibuya","year":"2006","unstructured":"Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1\/Flt-1): a dual regulator for angiogenesis. Angiogenesis. 2006;9:225\u201330.","journal-title":"Angiogenesis"},{"key":"577_CR49","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10555-006-9036-9","volume":"25","author":"RN Kaplan","year":"2006","unstructured":"Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the \u2018pre-metastatic niche\u2019: within bone and beyond. Cancer Metastasis Rev. 2006;25:521\u20139.","journal-title":"Cancer Metastasis Rev"},{"key":"577_CR50","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/neuonc\/now043","volume":"18","author":"E Szabo","year":"2016","unstructured":"Szabo E, Schneider H, Seystahl K, Rushing EJ, Herting F, Weidner KM, Weller M. Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. Neuro-Oncology. 2016;18:1242\u201352.","journal-title":"Neuro-Oncology"},{"key":"577_CR51","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1517\/14728220902806444","volume":"13","author":"H Miletic","year":"2009","unstructured":"Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets. 2009;13:455\u201368.","journal-title":"Expert Opin Ther Targets"},{"key":"577_CR52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10014-010-0007-z","volume":"28","author":"M Onishi","year":"2011","unstructured":"Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol. 2011;28:13\u201324.","journal-title":"Brain Tumor Pathol"},{"key":"577_CR53","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1101\/gad.1890510","volume":"24","author":"MM Inda","year":"2010","unstructured":"Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010;24:1731\u201345.","journal-title":"Genes Dev"},{"key":"577_CR54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13046-016-0482-0","volume":"36","author":"I Ylivinkka","year":"2017","unstructured":"Ylivinkka I, Sihto H, Tynninen O, Hu Y, Laakso A, Kivisaari R, et al. Motility of glioblastoma cells is driven by netrin-1 induced gain of stemness. J Exp Clin Cancer Res. 2017;36:9.","journal-title":"J Exp Clin Cancer Res"},{"key":"577_CR55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/neuonc\/nov288","volume":"18","author":"P Baumgarten","year":"2016","unstructured":"Baumgarten P, Blank AE, Franz K, Hattingen E, Dunst M, Zeiner P, et al. Differential expression of vascular endothelial growth factor a, its receptors VEGFR-1, \u22122, and \u22123 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. Neuro-Oncology. 2016;18:173\u201383.","journal-title":"Neuro-Oncology"},{"key":"577_CR56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.biopha.2016.01.005","volume":"78","author":"K Park","year":"2016","unstructured":"Park K, Amano H, Ito Y, Kashiwagi S, Yamazaki Y, Takeda A, et al. Vascular endothelial growth factor receptor-1 (VEGFR-1) signaling enhances angiogenesis in a surgical sponge model. Biomed Pharmacother. 2016;78:140\u20139.","journal-title":"Biomed Pharmacother"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-017-0577-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T03:04:05Z","timestamp":1569985445000},"score":1,"resource":{"primary":{"URL":"http:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-017-0577-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,10]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["577"],"URL":"https:\/\/doi.org\/10.1186\/s13046-017-0577-2","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,10]]},"article-number":"106"}}